Vnitr Lek 2022, 68(5):309-314 | DOI: 10.36290/vnl.2022.065

Inflammation and vascular diseases

Debora Karetová, Jan Bultas
II. interní klinika kardiologie a angiologie 1. LF UK a VFN Praha
Ústav farmakologie 3. LF UK Praha

Chronic venous disease and cardiovascular atherothrombotic diseases have a high prevalence worldwide. The aetiopathogenesis of both these vascular conditions may share certain aetiopathogenetic moments. Abnormal blood flow, altered intravascular tension, and subsequent endothelial dysfunction may all play an important role. Another plausible alternative is the correlation of some risk factors of both diseases, in particular obesity and metabolic syndrome with all its components and an impact on atherogenesis as well as chronic venous disease. The relationship may even be causal, that is a chronic vessel wall inflammation which is present in advanced venous insufficiency might accelerate atherogenesis. On the other hand, altered haemodynamics in right ventricular dysfunction with a subsequent elevation in venous pressure can worsen or induce venous insufficiency, and/or undoubtedly cause symptoms and signs typical of chronic venous disease. As suggested by the findings published recently in the Gutenberg Health Study, particularly its subanalysis regarding the relationship of venous disease and cardiovascular diseases, the venous and arterial beds can be affected by common aetiopathogenetic factors or both the systems can interfere with each other.

Keywords: atherosclerosis, atherothrombosis, chronic venous disease, inflammation, Gutenberg Health Study.

Accepted: August 4, 2022; Published: August 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karetová D, Bultas J. Inflammation and vascular diseases. Vnitr Lek. 2022;68(5):309-314. doi: 10.36290/vnl.2022.065.
Download citation

References

  1. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond). 2018 Jun 21;132(12):1243-1252. doi: 10.1042/CS20180306. Go to original source... Go to PubMed...
  2. Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y, Aung LHH, Li PF, Yu T, Chu XM. NLRP3 inflammasome in endothelial dysfunction. Cell Death, DiS. 2020 Sep 18;11(9):776. doi: 10.1038/s41419-020-02985-x. Go to original source... Go to PubMed...
  3. Marchio P, Guerra‑Ojeda S, Vila JM et al, Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2019 Jul 1;2019:8563845. Go to original source... Go to PubMed...
  4. Sanz M, Del Castillo AM, Jepsen S, et al. Periodontitis and Cardiovascular Diseases. Consensus Report. Glob Heart. 2020;15(1):1. Go to original source... Go to PubMed...
  5. Dietrich T, Sharma P, Walter C et al. The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease. Journal of Clinical Periodontology. 2013;40:S70-84 Go to original source... Go to PubMed...
  6. Garshick MS, Ward NL, Krueger JG et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(13):1670-1680. Go to original source... Go to PubMed...
  7. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012;148:1244-50. Go to PubMed...
  8. Ridker, PM et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377:1119-1131. Go to original source... Go to PubMed...
  9. Tardif JC. et al. Efficacy and safety of low- dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-2505. Go to original source... Go to PubMed...
  10. Nidorf SM, Eikelboom JW, Budgeon CA et al. Low- dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-410. Go to original source... Go to PubMed...
  11. Nidorf SM et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-1847. Go to original source... Go to PubMed...
  12. Tisato V, Zauli G, Voltan R et al. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro‑inflammatory phenotype. PLoS ONE 2012, 7, e39543. Go to original source... Go to PubMed...
  13. Raffetto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol. 2014;33(3):212-221. Go to PubMed...
  14. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol 2018;17:121. Go to original source... Go to PubMed...
  15. Reka IE, Imre M. Socio‑demographic Characteristics of Patients Diagnosed with Advanced Chronic Venous Insufficiency (C4-C6) Correlated with Clinical and Para‑clinical Findings. Acta Marisiensis Ser Medica. 2015;61:94-99. Go to original source...
  16. Singer AJ, Tassiopoulos A, Kirsner RS. Evaluation and Management of Lower‑Extremity Ulcers. N Engl J Med 2017;377:1559-1567. Go to original source... Go to PubMed...
  17. Saxton SN, Clark BJ, Withers SB, Eringa EC, Heagerty AM. Mechanistic Links Between Obesity, Diabetes, and Blood Pressure: Role of Perivascular Adipose Tissue. Physiol Rev 2019;99:1701-1763. Go to original source... Go to PubMed...
  18. Prochaska JH, Arnold N, Falcke A, Kopp S, Schulz A, Buch G, Moll S, PanovaNoeva M, Junger C, Eggebrecht L, Pfeiffer N, Beutel M, Binder H, Grabbe S, Lackner KJ, Cate‑Hoek A, Espinola‑Klein C, Munzel T, Wild PS. Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. Eur Heart J 2021;doi:10.1093/eurheartj/ehab495Uvolnění vazoadhezních molekul, cytokinů, chemokinů a metaloproteázInfiltrace makrofágů do cévní stěny, dysfunkce endotelu, změna fenotypu myocytů a jejich proliferace Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.